Last mentioned: Mar 17, 2026
Clinical Evaluation
Anticipated delivery of therapeutic batches for Phase I/II clinical trials.
cGMP Manufacturing
Commencement of current Good Manufacturing Practice (cGMP) runs for clinical supply.
Process Development
Expected completion of initial process optimization and scale-up activities.
Program Initiation
BioCina officially starts the comprehensive manufacturing program for the Patry therapeutic.
BioCina has initiated a comprehensive manufacturing program for Patry, a proprietary injectable therapeutic designed to alleviate delirium. This partnership marks a critical transition from clinical development to scalable production, leveraging BioCina's specialized microbial fermentation capabilities.
BioCina has launched a comprehensive manufacturing program for the Patry proprietary injectable therapeutic, a novel treatment designed to alleviate delirium. This partnership marks a critical milestone in bringing a specialized solution to a high-need clinical area with limited current treatment options.